Unichem gets EIR from USFDA for Pithampur, Roha facilities
New Delhi: Drug firm Unichem Laboratories has recently announced its active pharmaceutical ingredient (API) manufacturing units at Pithampur and Roha have received Establishment Inspection Reports(EIR) from the US health regulator.
The company's API manufacturing facilities have received EIRs from the United States Food and Drug Administration (USFDA) indicating closure of inspections at both the facilities, Unichem Laboratories said in a filing to the BSE.
The inspection at Pithampur was conducted by the FDA from July 23 to July 27, 2018, and the inspection at Roha was conducted by the FDA from July 30 to August 3, 2018, it added.
The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
The company's API manufacturing facilities have received EIRs from the United States Food and Drug Administration (USFDA) indicating closure of inspections at both the facilities, Unichem Laboratories said in a filing to the BSE.
The inspection at Pithampur was conducted by the FDA from July 23 to July 27, 2018, and the inspection at Roha was conducted by the FDA from July 30 to August 3, 2018, it added.
The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd